Table 2.
Description of the therapeutic indication of the vaccines under study
Vaccine | Therapeutic indication (extracted from http://www.medicines.org.uk/emc on 14 August 2014) |
---|---|
Engerix™ | Active immunization against hepatitis B virus infection caused by all known subtypes in non-immune subjects |
Havrix™ (adult and pediatric) | Active immunization against infections caused by hepatitis A virus |
Cervarix™ | Vaccine for use from the age of 9 years for the prevention of premalignant genital (cervical, vulvar, and vaginal) lesions and cervical cancer causally related to certain oncogenic human papillomavirus types |
Infanrix™ | Vaccine indicated for booster vaccination against diphtheria, tetanus, pertussis, and poliomyelitis diseases in individuals from 16 months to 13 years of age inclusive who have previously received primary immunization series against these diseases |
Infanrix™ Hib | Active immunization against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b disease from the age of 2 months |
Rotarix™ | Active immunization of infants aged 6–24 weeks for prevention of gastroenteritis due to rotavirus infection |
Fluarix™ | Prophylaxis of influenza, especially those who run an increased risk of associated complications. Fluarix™ is indicated in adults and children from 6 months of age |
Twinrix™ (adult and pediatric) | Indicated for individuals who are at risk of both hepatitis A and hepatitis B infection |